Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Current Assets (2019 - 2025)

Cyclerion Therapeutics has reported Current Assets over the past 7 years, most recently at $5.1 million for Q3 2025.

  • Quarterly results put Current Assets at $5.1 million for Q3 2025, up 42.76% from a year ago — trailing twelve months through Sep 2025 was $5.1 million (up 42.76% YoY), and the annual figure for FY2024 was $4.2 million, down 47.35%.
  • Current Assets for Q3 2025 was $5.1 million at Cyclerion Therapeutics, up from $4.0 million in the prior quarter.
  • Over the last five years, Current Assets for CYCN hit a ceiling of $73.0 million in Q2 2021 and a floor of $3.5 million in Q3 2024.
  • Median Current Assets over the past 5 years was $8.3 million (2023), compared with a mean of $21.7 million.
  • Biggest five-year swings in Current Assets: tumbled 80.54% in 2023 and later soared 42.76% in 2025.
  • Cyclerion Therapeutics' Current Assets stood at $55.5 million in 2021, then tumbled by 73.28% to $14.8 million in 2022, then plummeted by 45.86% to $8.0 million in 2023, then crashed by 47.35% to $4.2 million in 2024, then rose by 19.88% to $5.1 million in 2025.
  • The last three reported values for Current Assets were $5.1 million (Q3 2025), $4.0 million (Q2 2025), and $4.5 million (Q1 2025) per Business Quant data.